Biogen (BIIB) Q3 2026 Earnings
Non-GAAP EPS of $2.62 includes $284 million of acquired IPR&D, upfront and milestone expense, primarily related to the acquisition of RayThera Inc. GAAP EPS of $(0.14) further includes $194.8 million amortization of inventory fair value step-up, $172.8 million amortization of acquired intangible assets, $82.1 million restructuring charges, $33.3 million loss on equity security investments, and $26.6 million litigation matters.
How Did BIIB Stock React to Q3 2026 Earnings?
Did BIIB Beat Earnings? Q3 2026 Results
Yes. Biogen reported Q3 2026 earnings of $2.62 a share on Oct 28, 2026, beating the $1.97 consensus estimate by 32.7%. Revenue was $2.8B against a $2.6B estimate.
Biogen delivered a convincing beat across the board in Q3 2026, with adjusted non-GAAP EPS of $2.62 clearing the $1.97 consensus by 32.74%, marking the company's fifth consecutive quarter of beating EPS estimates. Revenue of $2.80 billion rose 14.2% year over year and topped forecasts by 6.54%, driven primarily by the first full quarter of SYFOVRE and EMPAVELI contributions following the Apellis Pharmaceuticals acquisition that closed in May 2026. The newly formed Specialized Immunology segment generated $243.00 million in combined revenue, while the broader Growth Portfolio, now representing 63% of Core Pharmaceutical revenue, surged 49% year over year to $1.26 billion, offsetting continued erosion in the legacy MS franchise where product revenue fell 13% to $919.00 million. GAAP EPS swung to a loss of $0.14, weighed down by $283.80 million in acquired IPR&D charges tied largely to the RayThera Inc. acquisition. Looking ahead, Biogen raised the lower end of its full-year 2026 non-GAAP EPS guidance to $12.20-$13.00, with multiple Phase 3 readouts on the horizon beginning with litifilimab in SLE in December 2026.
- Growth Portfolio revenue of $1.26 billion increased 49% YoY, representing 63% of Core Pharmaceutical revenue
- First full quarter contribution from acquired Apellis products (SYFOVRE and EMPAVELI)
- SPINRAZA accelerated conversion to high-dose regimen exceeding Company expectations across all launched markets
- LEQEMBI continued sequential growth with U.S. in-market sales of $107 million
- SKYCLARYS benefiting from increased U.S. and international demand and favorable U.S. inventory dynamics
- ZURZUVAE strong continued demand growth
- SYFOVRE volume growth up 18% YoY with commercial injections reaching highest quarterly level since launch
- EMPAVELI strong demand growth in nephrology indications
“Our third quarter results demonstrate that Biogen has returned to growth. We're seeing the strength of our Growth Portfolio – including the first full quarter of results from Apellis products – which helped drive double-digit revenue growth and an approximately 50% year-over-year increase from our growth products.”
Biogen CEO, on the earnings call
What Is Biogen's Outlook?
Biogen raised the lower end of its full year 2026 Non-GAAP diluted EPS guidance range to $12.20-$13.00 from $12.00-$13.00, reflecting ongoing business strength and Apellis dilution favorability. Underlying guidance (excluding ~$3.20 of acquired IPR&D/upfront/milestone impact and ~$0.55 of Apellis dilution) is $15.95-$16.75. Full year total revenue is expected to increase by a mid-single digit percentage for 2026 vs 2025, driven by continued growth from the Growth Portfolio. Combined Non-GAAP R&D and SG&A expense expected to be approximately $4.95 billion for full year 2026. Multiple Phase 3 readouts expected: litifilimab in SLE (TOPAZ-1 and TOPAZ-2) in first half of December 2026; litifilimab in CLE and felzartamab in antibody-mediated rejection in H1 2027; zorevunersen in Dravet syndrome in Q3 2027.
BIIB YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $2.8B | $2.5B | +14.2% |
| Gross Profit | $2.1B | $1.6B | +30.3% |
BIIB Revenue by Segment
BIIB Revenue by Geography
When Does Biogen Report Next?
Figures from SEC filings and company reports. Not investment advice.